{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T18:29:24Z","timestamp":1783967364466,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T00:00:00Z","timestamp":1761436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015631","name":"Merck Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015631","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jhepr.2025.101658","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:19:07Z","timestamp":1761959947000},"page":"101658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib \u2013 A phase II trial (PEMRAD)"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8690-403X","authenticated-orcid":false,"given":"Grainne M.","family":"O\u2019Kane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruz","family":"Mesci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond W.","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2734-7090","authenticated-orcid":false,"given":"Aisling","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9578-8384","authenticated-orcid":false,"given":"Cynthia M.","family":"Bocaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giselle M.","family":"Boukhaled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-6731","authenticated-orcid":false,"given":"Holly","family":"Acton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Doddington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowena","family":"Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo M.L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Noamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9542-7530","authenticated-orcid":false,"given":"Harry","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhoda","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0649-0760","authenticated-orcid":false,"given":"Anna","family":"Dodd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben X.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Knox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jhepr.2025.101658_bib1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"7","author":"Collaborators","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jhepr.2025.101658_bib2","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhepr.2025.101658_bib3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhepr.2025.101658_bib4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jhepr.2025.101658_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2025.101658_bib6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"issue":"10064","key":"10.1016\/j.jhepr.2025.101658_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jhepr.2025.101658_bib8","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.jhepr.2025.101658_bib9","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.jhepr.2025.101658_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhepr.2025.101658_bib11","article-title":"Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: the NRG oncology\/RTOG 1112 phase 3 randomized clinical trial","author":"Dawson","year":"2024","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.jhepr.2025.101658_bib12","first-page":"655","article-title":"Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and\/or contralateral portal vein invasion in IMbrave150","volume":"13","author":"Finn","year":"2024","journal-title":"Liver Cancer"},{"issue":"6","key":"10.1016\/j.jhepr.2025.101658_bib13","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jhep.2019.01.028","article-title":"Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival","volume":"70","author":"Llovet","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101658_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2025.101658_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","author":"Sangro","year":"2025","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jhepr.2025.101658_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005457","article-title":"Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study","volume":"10","author":"de la Torre-Alaez","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.jhepr.2025.101658_bib17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.hpb.2017.04.016","article-title":"Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis","volume":"19","author":"Silva","year":"2017","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jhepr.2025.101658_bib18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.radonc.2020.11.033","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion","volume":"156","author":"Munoz-Schuffenegger","year":"2021","journal-title":"Radiother Oncol"},{"issue":"6","key":"10.1016\/j.jhepr.2025.101658_bib19","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/j.jhep.2024.01.007","article-title":"Radiotherapy following intrahepatic progression on immunotherapy in advanced hepatocellular carcinoma","volume":"80","author":"Chan","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101658_bib20","doi-asserted-by":"crossref","first-page":"S597","DOI":"10.1016\/j.annonc.2023.09.2097","article-title":"954P Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: a single arm, phase II clinical trial","volume":"34","author":"Zhang","year":"2023","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.jhepr.2025.101658_bib21","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1001\/jamaoncol.2024.4085","article-title":"Complete response to locoregional therapy plus immunotherapy for hepatocellular carcinoma","volume":"10","author":"Chiang","year":"2024","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.jhepr.2025.101658_bib22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.jhepr.2025.101658_bib23","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","article-title":"Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity","volume":"2","author":"Ho","year":"2021","journal-title":"Nat Cancer"},{"issue":"8","key":"10.1016\/j.jhepr.2025.101658_bib24","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jhepr.2025.101658_bib25","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.4049\/jimmunol.1402711","article-title":"CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients","volume":"194","author":"Djenidi","year":"2015","journal-title":"J Immunol"},{"issue":"13","key":"10.1016\/j.jhepr.2025.101658_bib26","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1158\/1078-0432.CCR-17-2257","article-title":"CD103(+) tumor-resident CD8(+) T cells are associated with improved survival in immunotherapy-naive melanoma patients and expand significantly during anti-PD-1 treatment","volume":"24","author":"Edwards","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jhepr.2025.101658_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12876-020-1177-8","article-title":"Prognostic value of peripheral blood natural killer cells in colorectal cancer","volume":"20","author":"Tang","year":"2020","journal-title":"BMC Gastroenterol"},{"issue":"8","key":"10.1016\/j.jhepr.2025.101658_bib28","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1158\/2326-6066.CIR-18-0896","article-title":"High numbers of circulating CD57(+) NK cells associate with resistance to HER2-specific therapeutic antibodies in HER2(+) primary breast cancer","volume":"7","author":"Muntasell","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jhepr.2025.101658_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.872353","article-title":"The prognostic value of natural killer cells and their receptors\/ligands in hepatocellular carcinoma: a systematic review and meta-analysis","volume":"13","author":"Xue","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jhepr.2025.101658_bib30","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jhep.2020.07.026","article-title":"Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma","volume":"73","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhepr.2025.101658_bib31","article-title":"Effect of cytokines on advanced hepatocellular carcinoma prognosis receiving radiotherapy and tislelizumab plus anlotinib: a single-center phase II clinical trial","volume":"14","author":"Lin","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2025.101658_bib32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41698-018-0065-y","article-title":"Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy","volume":"2","author":"Hong","year":"2018","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.jhepr.2025.101658_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102071","article-title":"Comprehensive analysis of CXCL10 and MIP-3a reveals their potential clinical application in hepatocellular carcinoma","volume":"48","author":"Yang","year":"2024","journal-title":"Transl Oncol"},{"issue":"3","key":"10.1016\/j.jhepr.2025.101658_bib34","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.18632\/oncotarget.14095","article-title":"CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis","volume":"8","author":"Jin","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhepr.2025.101658_bib35","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","year":"2024","journal-title":"J Hepatol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925003404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925003404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:22:05Z","timestamp":1777634525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555925003404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2589555925003404"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101658","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib \u2013 A phase II trial (PEMRAD)","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101658"}}